about
Myelodysplastic syndromes: what do hospitalists need to know?Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution.There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.Depletion of cytotoxic T-cells does not protect NUP98-HOXD13 mice from myelodysplastic syndrome but reveals a modest tumor immunosurveillance effect.Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease.Identifying the similarities and differences between single nucleotide polymorphism array (SNPa) analysis and karyotyping in acute myeloid leukemia and myelodysplastic syndromes.Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemiaMolecular pathogenesis of myelodysplastic syndromes.Myeloproliferation and hematopoietic stem cell dysfunction due to defective Notch receptor modification by O-fucose glycans.Detection of copy number alterations in acute myeloid leukemia and myelodysplastic syndromes.Genome-wide arrays in routine diagnostics of hematological malignancies.Myelodysplastic syndromes: toward a risk-adapted treatment approach.What Is the Clinical Utility of Repeat SNP Array Testing in the Follow-up of Myeloid Neoplasms?: A Retrospective Analysis of 44 Patients With Serial SNP Arrays.Techniques for detecting chromosomal aberrations in myelodysplastic syndromesMultiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.
P2860
Q27011372-1174D5C1-6CB0-472F-82CD-4914EF434FD7Q33405487-57AF58BF-B7AC-4293-A924-4F300AFCC985Q34049017-DB07FF2E-A233-468F-A93F-163452F77BE7Q34273750-3C837290-EDF3-492D-BDD7-E81F611704A3Q34667249-9C72EE5F-BCCC-49A7-B089-0F469C95D456Q35054860-79B2F99A-1D11-4377-A58D-2D838667F1B1Q36498395-F629CC24-9465-4E30-935E-A15137CD9BAEQ37724602-538C06F9-ECA0-4054-8C69-021F73CF955FQ37993403-588B0B55-A1B5-4353-8386-3A1DE864EF57Q37999070-C34A472A-50E5-4402-B7FB-455274350C09Q38001406-3C6BC04B-768B-47BB-A3B0-47BD1FD7D3CCQ38149315-BB5D3DC2-A7D7-41F0-B793-5731997DB983Q40250091-5698A2D7-BDAB-4B30-B84B-19DD51CFF6DDQ41791233-4F240837-2E0C-40D0-BF58-36B695B15071Q46045890-D5C6D3C4-88A0-4C23-A395-578BE6B4AAA3Q48730157-E83B142D-A735-454E-81F9-EE1DE6986A96
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Updates in cytogenetics and molecular markers in MDS.
@en
Updates in cytogenetics and molecular markers in MDS.
@nl
type
label
Updates in cytogenetics and molecular markers in MDS.
@en
Updates in cytogenetics and molecular markers in MDS.
@nl
prefLabel
Updates in cytogenetics and molecular markers in MDS.
@en
Updates in cytogenetics and molecular markers in MDS.
@nl
P2093
P2860
P1476
Updates in cytogenetics and molecular markers in MDS.
@en
P2093
Anita Schwandt
Jaroslaw P Maciejewski
Ramon V Tiu
Valeria Visconte
P2860
P2888
P304
P356
10.1007/S11899-011-0081-2
P577
2011-06-01T00:00:00Z